Business Wire

‘A Vision for Lupus’ Report, Published Ahead of World Lupus Day, Highlights an Important Need to Improve Quality of Care for Lupus Patients

Share

To support patients, care givers and healthcare professionals on World Lupus Day, an expert-led report, ‘A Vision for Lupus’, has today been published to help highlight gaps and inconsistencies in care and areas for action to address the gaps that can often exist for patients and their families living with lupus, a chronic, inflammatory, autoimmune disease that affects approximately five million people globally.1,2 GSK conceived, developed and led the ‘A Vision for Lupus’ initiative in collaboration with a Global Multidisciplinary Steering Committee, and the report outlines three specific, patient-centred Calls to Action to the lupus community:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190508005793/en/

Vision for Lupus Infographic (Graphic: Business Wire)

Vision for Lupus Infographic (Graphic: Business Wire)

1) Raise awareness of lupus amongst the general public, people living with lupus, their families and healthcare providers to support early diagnosis and help people with lupus feel more acknowledged, understood and supported;

2) Improve access to specialist and multidisciplinary lupus clinics to address the aspects of this complex, multisystem disease;

3) Raise awareness of ongoing clinical trials to facilitate access to research participation enabling people with lupus to make autonomous decisions in the management of their condition.

Professor David D’Cruz, Chair of the ‘A Vision for Lupus’ Steering Committee and Consultant Rheumatologist at Guy’s and St Thomas’ Hospital, London, UK said: “There is an important need to address the significant barriers to high-quality care that can still exist for people with lupus. By highlighting Calls to Action, we hope that the ‘A Vision for Lupus’ report will stimulate discussion to drive positive change in three key areas; disease awareness, service delivery and clinical research. We urge people to visit www.visionforlupus.org to access the report so as to understand opportunities for playing a part in improving the quality of life for people with lupus.”

Duane Peters, Senior Communications Strategist at the Lupus Foundation of America Inc. and Staff Coordinator for the World Lupus Federation said: “I am pleased to support the launch of the ‘A Vision for Lupus’ report on World Lupus Day, an important international platform to generate awareness about the condition. Lupus can be a devastating autoimmune disease disproportionately impacting women in the prime of their lives, compromising everyday plans, social lives and aspirations for a career and family.”

World Lupus Day was established in 2004 to raise awareness of the disease and its impact on patients, with the aim of improving the quality of life for people affected by this potentially fatal disease. More needs to be done to bring the condition into the public eye; over half (51%) of respondents to a recent global survey were unaware that lupus is a disease, and amongst those who were aware, 41% could not name any complications associated with the condition.3 Public misconceptions about lupus may contribute to a lack of empathy for people with lupus, whose symptoms are often “invisible” to others, leading to them feeling frustrated, inadequately understood, isolated and alone.4

Alain Cornet, General Secretary, Lupus Europe and Steering Committee member said: “The ‘A Vision for Lupus’ report is an important step towards changing the future for people with lupus, so that they have an improved quality of life, feeling acknowledged, understood and supported. We hope that this report will help as many people as possible get access to specialist and multidisciplinary lupus clinics where they can receive quality care for all aspects of this complex multisystem disease, and where they are encouraged and supported to take part in managing their own disease, whether through therapeutic education or participating in clinical research.”

Ravi Rao, Immunology and Specialty Medical Head, GSK said: “GSK is extremely grateful to all members of the Steering Committee who have contributed to the development of the ‘A Vision for Lupus’ report. The report highlights the need for improvement in diagnosis, better multi-disciplinary management and the importance of clinical research in lupus. As part of GSK’s commitment to help the 5 million people affected with lupus worldwide, we will continue to play our part to address these calls to action. We hope this report will help raise the global voice of the lupus patient community and drive a much-needed change to improve the lives of patients living with lupus.”

Notes to editors

About Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus (SLE), also known as lupus, is a chronic, inflammatory, autoimmune disease affecting 5 million people worldwide with 70%-90% of these cases appearing in females.2,5,6 The body produces antibodies that attack its own healthy cells and tissues in addition to producing antibodies to protect against infection.2,7 Lupus can affect many different parts of the body, including the joints, skin, kidneys, heart, lungs, brain and blood vessels.

The most common symptoms include painful and swollen joints, extreme fatigue, skin rashes, anaemia, and kidney problems. Typically, people with lupus have periods of illness, called flares, and periods of relative wellness, called remission.8 Severity of the illness can vary; some people with lupus can continue to live a normal life, while others experience frequent, life-threatening flares that require critical care.8 As there is no cure for lupus,5 the goals of treatment are to achieve and maintain disease remission, prevent flares and prevent damage to the body’s organs and tissues.9

About ‘A Vision for Lupus’

In 2018, GSK convened a global multidisciplinary Steering Committee comprising a person with lupus, a patient advocacy expert, representation from international lupus patient organisations and clinicians specialising in the condition to discuss the future ‘A Vision for Lupus’. The two advocacy groups that form part of the Steering Committee are the Lupus Foundation of America and Lupus Europe, both of whom are members of the World Lupus Federation, a global coalition of patient groups which coordinate efforts on World Lupus Day. Both the World Lupus Federation and Lupus Europe have received grants from GSK.

The Chair of the ‘A Vision for Lupus’ Steering Committee is Professor David D’Cruz, Consultant Rheumatologist at Guy’s and St Thomas’ Hospital, London, UK. Other members include Dr. Chiara Tani, Rheumatologist, University of Pisa, Italy; Dr. Patricia Cagnoli, Rheumatologist, University of Michigan, USA; Duane Peters, Senior Communications Strategist at the Lupus Foundation of America Inc. and Staff Coordinator for the World Lupus Federation; Alain Cornet, General Secretary, Lupus Europe; and Neil Betteridge, Patient Engagement Expert. A person living with lupus, who wished to remain anonymous, contributed to early discussions on the report.

About the World Lupus Federation

The World Lupus Federation is a coalition of lupus patient organisations from around the world. They are united with the mission to improve the quality of life for all people living with lupus. The World Lupus Federation coordinates awareness, education and advocacy initiatives with support from its global affiliates.10

About World Lupus Day

World Lupus Day is held annually on 10 May. This year will be the 16th annual observance of World Lupus Day, a global call-to-action on behalf of the millions of people around the world who are affected by lupus. The day serves as an opportunity to rally stakeholders around the world for the common purpose of drawing attention to and directing resources to end the suffering caused by this disabling and potentially fatal disease.11

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2017

References

1 Lupus Foundation of America. Facts and Statistics. Available at: https://www.lupus.org/resources/lupus-facts-and-statistics Last accessed: April 2019

2 Lupus Foundation of America. What is lupus? Available at: https://resources.lupus.org/entry/what-is-lupus. Last accessed April 2019

3 World Lupus Federation, World Lupus Day International Survey (2018)

4 World Lupus Federation, Lupus Knows No Boundaries E-Report. (2017) Available at: http://www.worldlupusday.org/e-report.html Last accessed April 2019

5 National Health Service. Lupus. Available at: https://www.nhs.uk/conditions/lupus/. Last accessed: April 2019

6 Beeson PA. Age and Sex Association of 40 Autoimmune Disease. Am J Med 1994; 96:457-462.

7 NIH National Institute of Arthritis and Musculoskeletal Diseases. Handout on health: systemic lupus erythematosus. Available at: http://www.niams.nih.gov/Health_Info/Lupus/. Last accessed: April 2019

8 McElhone K, Abbott J, Gray J, et al. Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study. Lupus. 2010;19:1640-7

9 Cunha, JS. Et al. “Systemic lupus erythematosus: A review of the clinical approach to diagnosis and update on current targeted therapies.” Rhode Island Medical Journal 99.12 (2016)

10 World Lupus Federation. United Lupus Groups Around the World. Available at: https://worldlupusfederation.org/ Last Accessed: April 2019

11 World Lupus Federation. World Lupus Day: About Lupus. Available at: http://www.worldlupusday.org/about-us.html Last accessed: April 2019

Registered in England & Wales:

No. 3888792

 
Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

Contact information

GSK enquiries:
UK Media enquiries:
Simon Steel
+44 (0) 20 8047 5502
(London)

Tim Foley
+44 (0) 20 8047 5502
(London)

Sam Kwong
+44 (0) 20 8047 5502
(London)

US Media enquiries:
Evan Berland
+1 215 751 5497
(Philadelphia)

Mary Anne Rhyne
+1 919 483 0492
(North Carolina)

Analyst/Investor enquiries:
Sarah Elton-Farr
+44 (0) 20 8047 5194
(London)

Danielle Smith
+44 (0) 20 8047 2406
(London)

James Dodwell
+44 (0) 20 8047 2406
(London)

Jeff McLaughlin
+1 215 751 7002
(Philadelphia)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gilead Announces Latest Data in Ongoing HIV Cure Research Program23.7.2019 23:00:00 EESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program. The Phase 1 and preclinical study results demonstrate that the TLR7 agonists vesatolimod (GS-9620) and GS-986 can induce immune activation and follow earlier preclinical research suggesting that TLR7 agonists can potentially lead to viral remission, as part of combination regimens. The HIV viral reservoir is present even in virologically suppressed individuals and its elimination is regarded as a main obstacle to achieving a cure. The data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “While treatments have improved dramatically, people living with HIV still face a lifetime of therapy and potential complications. That reality drives our ongoing pursuit of a cure for HIV,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses

Moody’s Analytics Wins Best Reporting System Provider in Waters Rankings23.7.2019 18:30:00 EESTPress release

Moody’s Analytics, a global provider of financial intelligence, has won the award for Best Reporting System Provider in the 2019 Waters Rankings. We earned this recognition for our regulatory reporting solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005679/en/ For banks and insurers, staying on top of regulatory changes is critical. Our end-to-end solution handles the entire reporting process, producing 3,000 different regulatory reports covering more than 50 jurisdictions. It automatically delivers all required updates well in advance of the relevant deadlines and makes it easy for clients to review, adjust, audit, and validate their reports. The Moody’s Analytics regulatory surveillance team boasts a wealth of experience in both local and international domains going back decades. They monitor more than 100 supervisor websites to ensure that our clients receive the updates they need in a timely fashion. “Regu

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®23.7.2019 18:00:00 EESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP). In a sub-analysis of the DISCOVER trial, Descovy reached intracellular drug concentration levels above the estimated protective threshold significantly more quickly than Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets; F/TDF), and additional pharmacokinetic data confirm that these drug concentration levels persist longer than Truvada. The results were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “Gilead is committed to driving advances in HIV prevention and supporting broader public health initiatives that are designed to reduce HIV infections,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “These

Velodyne Lidar Acquires Mapper.ai for ADAS Launch23.7.2019 18:00:00 EESTPress release

Velodyne Lidar, Inc. today announced it has acquired mapping and localization software as well as intellectual property assets from Mapper.ai. Mapper technology will enable Velodyne to accelerate development of Vella™, breakthrough software that establishes its directional view Velarray™ lidar sensor. The Velarray is the first solid-state Velodyne lidar sensor that is embeddable and fits behind a windshield, as an integral component for superior, more effective advanced driver assistance systems (ADAS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005257/en/ In addition to ADAS, Velodyne will incorporate Mapper technology into lidar-centric solutions for other emerging applications, including autonomous vehicles, last-mile delivery services, security, smart cities, smart agriculture, robotics, and unmanned aerial vehicles. (Photo: Business Wire) Mapper’s entire leadership and engineering teams will join Velodyne, bol

Wealthy Americans are increasingly willing to invest, new UBS survey finds23.7.2019 17:12:00 EESTPress release

US high net worth individuals and business owners are expressing growing intentions to invest as US markets continue to hit record highs in 2019, according to UBS Global Wealth Management's new quarterly Investor Sentiment survey. The survey, which polled more than 3,800 wealthy investors and entrepreneurs in 17 countries, also shows US investors remain positive on the U.S. stock market but continue to rank politics and the national debt as top concerns. Fifty percent of US investors see a diversified portfolio as a hedge against US-China trade tensions specifically, in line with UBS GWM's own views, compared with 41% who favor cash. Filippo Ilardi, US Client Strategy Officer at UBS Global Wealth Management, says: "We are pleased to see a substantial increase in investors willing to put more money in the market. Wealthy Americans are concerned about the political environment and US-China trade tensions but we are encouraged that they see diversification as an important way of managing

Andersen Global Expands into Ghana23.7.2019 16:30:00 EESTPress release

Ghana law firm, Sam Okudzeto & Associates, signed a collaboration agreement with Andersen Global, marking Andersen Global’s presence in 13 African countries and over 51 countries worldwide. Located in the capital of Accra, Sam Okudzeto & Associates is one of the largest law firms in Ghana. For the past 48 years, the firm has provided legal advice and guidance in the corporate and commercial areas, including patents and trademarks, mergers and acquisition, tax advisory, corporate banking, international trade and investment, debt recovery, mining and mineral law, industrial and labor, aviation, maritime law, petroleum oil and gas, and intellectual property. Sam Okudzeto & Associates founder and Managing Partner, Sam Okudzeto and Nene Amegatcher, have led the team since the establishment of the firm until Nene Amegatcher was elevated to the Supreme Court. The firm now has four partners and 18 lawyers who have gained international reputation for their keen knowledge and experience with Alt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom